Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 18,500 shares, a decline of 52.7% from the September 30th total of 39,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is presently 1.1 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Akari Therapeutics in a research note on Friday. They set a “sell” rating for the company.
View Our Latest Stock Report on Akari Therapeutics
Akari Therapeutics Price Performance
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Five stocks we like better than Akari Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- High Flyers: 3 Natural Gas Stocks for March 2022
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Which Wall Street Analysts are the Most Accurate?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.